Clinical characteristics and satisfaction with the fimasartan in Korean hypertensive patients: a prospective, cross-sectional and open-label, 8-week switching study (Kanarb-hypertension epidemiology medication satisfaction study; K-HEMS study)

Clinical characteristics and satisfaction with the fimasartan in Korean hypertensive patients: a prospective, cross-sectional and open-label, 8-week switching study (Kanarb-hypertension epidemiology medication satisfaction study; K-HEMS study)

Abstract Background Fimasartan (Kanarb; Boryung Pharmaceutical Co., Ltd., Seoul, Republic of Korea) is a non-protein angiotensin II receptor blocker that selectively blocks the AT1 receptor. No prior large-scale study has investigated the impact of demographics, disease, treatment, and clinical char...

Full description

Bibliographic Details
Main Authors: Dong Joo Oh, Su-Eun Han, Seung Hee Jeong, Myung Sook Hong, Seong Choon Choe
Format: Article
Language:English
Published: BMC 2018-09-01
Series:Clinical Hypertension
Subjects:
Fimasartan
Hypertension
Medication
Satisfaction
Online Access:http://link.springer.com/article/10.1186/s40885-018-0096-2

Similar Items

Similar Items